Phase 3 N=139 Levodopa for the Treatment of Residual Amblyopia
Amblyopia
Primary: Distribution of Amblyopic Eye Visual Acuity Change From Baseline — 0; 0; 2; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=44 Determination of Cell Population in Solution-Induced Corneal Staining (SICS) and Symptomatic Versus Asymptomatic Lens Wearers
Refractive Error · Dry Eye
Primary: Mean Number of Viable Epithelial Cells Collected Directly From the Ocular Surface After 2 Hours and 4 Hours of Wear, Phase 1 — 15; 20; 18; 22 cells
Phase 4 N=40 Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate
Multiple Sclerosis
Primary: Local Injection Site Reaction (0-6) Scale at Baseline, 2 Weeks — 3.39; 3.47 units on a scale — p=0.45
Phase 2 N=7 Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Pancreatic Adenocarcinoma · Recurrent Pancreatic Carcinoma · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Progression-free Survival — 2.5; 4.0 months — p=0.15
Phase 3 N=551 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Pulmonary Fibrosis
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks. — -207.32; -113.59 mL/year — p=0.0002
N/A N=63 Gastric Outlet Obstructions Tailored Covered Stents for GOO
Gastric Outlet Obstruction
Primary: Efficiency of Stents — 1; 7 participants
Phase 4 N=28 Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder
Bipolar Disorder
Primary: Number of Patients Whose Mood Improved According to MADRS and YMRS Scale Scores. — 4; 4; 4; 4 participants
Phase 2 N=40 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Skin Cancer
Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants
Phase 2 N=116 Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
B-cell Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle — 77.0 percentage of participants
Early Phase 1 N=103 Electrode-based Sensor for Non-invasive Fetal Heart Rate and EMG Monitoring With Improved Reliability
Pregnancy
Primary: Comparison of Electrode Sensor and TOCO Detection of Contraction Events, as Compared to IUPC — 2.98; 3.95 seconds
Phase 2 N=137 Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
Influenza
Primary: Time to Clinical Stability (Kaplan-Meier Estimate) — 23.7; 37.0; 28.1 hours — p=0.306
Phase 4 N=97 Effects of a Pectoralis Minor Muscle Stretching Protocol
Shoulder Pain
Primary: Pectoralis Minor Length After Pectoralis Minor Stretching Protocol — 16.38; 16.87 centimeters — p=<0.05
Phase 2 N=42 Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Non-Hodgkin's Lymphoma · Leukemia · Multiple Myeloma
Primary: The Comparison of Functional Immune Reconstitution at 6-9 Months Following Transplant as Measured by Antibody Response to Vaccination With Inactivated Hepatitis A or B…
Phase 3 N=441 NVA237 Versus Placebo 12-week Efficacy Study
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline of Standardized Area Under the Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) Post Dosing — 0.125; -0.014 liters*hr
N/A N=1,421 36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds
Meningitis · Meningococcal Disease
Primary: Summary of Diagnoses With Elevated Findings for Risk-Window vs. Control-Window Comparisons at the 5% Significance Level. — 1.4; 2.3 Events per 1,000 person-months